Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients

Background. Cinacalcet hydrochloride (KRN1493) acts on the parathyroid calcium receptors to suppress parathyroid hormone (PTH) secretion, and is already in wide use in the United States and the European countries. In this study, we examined the efficacy and safety of cinacalcet in Japanese patients...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2008-01, Vol.23 (1), p.328-335
Main Authors: Fukagawa, Masafumi, Yumita, Shigeru, Akizawa, Tadao, Uchida, Eiji, Tsukamoto, Yusuke, Iwasaki, Manabu, Koshikawa, Shozo
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
calcimimetics
calcium
Calcium - blood
calcium-sensing receptor
cinacalcet
Cinacalcet Hydrochloride
Double-Blind Method
Emergency and intensive care: renal failure. Dialysis management
Female
Glomerulonephritis
Humans
Hyperparathyroidism - blood
Hyperparathyroidism - drug therapy
Intensive care medicine
Japan
Male
Medical sciences
Middle Aged
Naphthalenes - therapeutic use
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Parathyroid Hormone - blood
phosphorus
Phosphorus - blood
PTH
Renal Dialysis
secondary hyperparathyroidism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Cinacalcet hydrochloride (KRN1493) acts on the parathyroid calcium receptors to suppress parathyroid hormone (PTH) secretion, and is already in wide use in the United States and the European countries. In this study, we examined the efficacy and safety of cinacalcet in Japanese patients on maintenance haemodialysis. Methods. One hundred forty-four patients with serum intact PTH (iPTH) levels ≥300 pg/ml were enrolled and randomly allocated to two groups assigned to receive either cinacalcet or placebo for 14 weeks. Cinacalcet was started at the dose of 25 mg/day and titrated up to 100 mg/day to achieve the target iPTH level of
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfm534